Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Power production in August 39.3 GWh

Normal winds in August resulted in a power production of 39.3 GWh, compared to the month´s budget of 38.9 GWh.Of this 22.0 GWh refers to Own wind power production and 17.3 GWh to Co-owned wind power production, compared to the month´s budget of 22.3 GWh and 16.6 GWh. Halmstad 10 September, 2018  ARISE AB (publ)  For further information, please contact Daniel Johansson, CEO Arise AB, +46 702 244 133 This information is information that Arise AB is obliged to make public pursuant to the EU MarketAbuse Regulation. The information was submitted for publication, through the

Scania and Stockholm School of Economics in new partnership

Scania will contribute to a new research centre at the Stockholm School of Economics (SSE) over the next ten years. The collaboration will focus on business models for the future transport ecosystem.“Scania is a technology-driven company, and as such, we are very successful. Both the industry and the transport sector are facing big changes, and future technology will create totally new business models within the ecosystem that Scania, its customers and partners operate. That perspective will be the focus of our partnership with Stockholm School of Economics,” says Henrik Henriksson,

Stena Line introduces first AI-assisted vessel

As a central part of Stena Line’s efforts to reduce fuel consumption and minimise environmental impact, the company is now running a pilot study where artificial intelligence technology is implemented on board vessels. Stena Line's Head of  AI Lars Carlsson and Senior Master Jan Sjöström discussing the new AI-model onboard Stena Scandinavica. In close collaboration with the technology company Hitachi, an AI-model is being developed that will help predict the most fuel-efficient way to operate a certain vessel on a specific route. The model will be a support for the captain and

Ahlstrom-Munksjö has resolved on a dividend of EUR 0.26 per share

AHLSTROM-MUNKSJÖ OYJ, STOCK EXCHANGE RELEASE September 10, 2018 at 11:00 EEST The Board of Directors of Ahlstrom-Munksjö Oyj has today resolved on a dividend in the amount of EUR 0.26 per each outstanding share. The dividend is being paid based on the decision by the Annual General Meeting of Shareholders’ held on March 21, 2018, which resolved on the payment of a dividend of EUR 0.52 per share to be paid in two instalments, and the subsequent decision by the Board of Directors on the record and payment dates for the second instalment. The first instalment of EUR 0.26 was paid on

Valmet launches Dashboards as part of Valmet DNA Automation System 2018 collection

Valmet Oyj's trade press release on September 10, 2018 at 11:00 a.m EET Valmet launches Valmet DNA Automation System collection 2018 introducing Valmet DNA Dashboard  concept that takes the visualization of process data to the next level. Valmet DNA collection 2018 introduces also improvements to the IO (Input/Output) products and OPC UA (Unified Architecture) communication capabilities. Valmet DNA Automation System is utilized in pulp, paper, energy and other process industries around the world. Valmet

Oncoral phase 1 results to be presented at ESMO congress in Munich

Ascelia Pharma announces today that results of the Phase I study for Oncoral has been accepted as a poster presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Munich, Germany, 19-23 October 2018.About the Phase I study: Oncoral has been evaluated in an investigator sponsored Phase I trial at the Department of Oncology at Herlev Hospital in Denmark. The study was a dose-escalating safety, tolerability and pharmacokinetics study of orally administered Oncoral in adult patients with advanced solid tumours. The objectives of the study were to determine the

Gaining serenity at the airport

Air travellers need a safe and peaceful place in the middle of busy airports. Thanks to GoSleep, now they have it.It’s happened to every traveller: you have a long layover and wander the terminal to find a peaceful place to relax. GoSleep Pod provides what every stressed traveller needs with a quiet, private place to work, relax or take a nap. “Passenger feedback has been overwhelmingly positive, confirming what we knew all along – this is a product that people want and need when travelling,” says Jussi Piispanen, GoSleep managing director.  Building on the long history of Finnish

Skanska builds school facility in Pullman, Washington, USA for USD 52 M, about SEK 470 M

Skanska has signed a contract with Washington State University (WSU) to build the Plant Sciences Building at the WSU Pullman campus in Pullman, Washington, USA. The contract is worth USD 52 M, about SEK 470 million, which will be included in the US order bookings for the third quarter of 2018.The contract consists of the construction of an approximately 7,700 square meter facility to carry out fundamental plant science research. The four-story building will house an open, modular wet-lab space; shared support functions; and office space for principal investigators, staff and research

The shareholder base in Bactiguard is broadened through a transaction comprising 6.6 million shares

The main shareholders in Bactiguard Holding AB (publ) broaden the shareholder base and increase the free float in the company's share through a secondary sale of existing shares to three Swedish institutional owners. The transaction comprises 6.63 million B-shares at the price of SEK 39 per share and the total value amounts to SEK 258.6 million."For a period of time we have been working on broadening the institutional ownership in Bactiguard and increasing liquidity in the stock. We have now sold a significant number of shares to three reputable Swedish institutions. Thereby, we have

ExpreS2ion’s joint venture, AdaptVac, receives notice of allowance in the U.S. for its breast cancer vaccine patent

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that its joint venture AdaptVac has received a notice of allowance in the USA for its patent application covering its novel vaccine treatment for HER2-positive breast cancer. This means that the patent is expected to be issued shortly, which is an important step forward for the project and documenting the patentability of the virus-like-particle (VLP) technology platform. After final approval, the patent will be valid at least 20 years from the priority date, 15-01-2015.“This is a major

IQwave™ D-EECT comes out better than the ESOPE protocol in its first publication

A Case study performed in Chennai in India under the leadership of Dr. Kalavathy as leading physician, Prof Emeritus Bertil Persson as Corresponding author was published in “Trends in Cancer Research” in its 13th editions 2018, a scientific cancer paper in India.In the conclusions of this publication the author says: ”In all of the evaluable tumours the objective responses were found to be 100%, with complete remissions at 18%, and partial remissions at 82%. No progressive disease was recorded, and the average weighted response became 45 ±17%.” Even if the populations was limited to

H & D Wireless becomes new members of Odette

Nasdaq First North-listed H&D Wireless, which develops and sells IoT modules and RTLS-positioning services (real time location service) to the manufacturing industry, becomes members of the cooperation body Odette Sweden, to contribute to the standardization of Industry 4.0 solutions in the automotive industry."The introduction of Odette standards already today results in optimization of transport, reduced capital tied to materials and less production stoppages and the introduction of Odette’s standard for digital messages in GEPS ™ tags enables the automotive industry real-time tracking of

Notification of primary insider trading cf. STA Sec. 4-2

Oslo, 10 September 2018With reference to Section 4-2 of the Norwegian Securities Trading Act ("STA"), kindly note the following primary insider trade:Name of listed entity: MPC Container Ships ASAISIN number: NO0010791353Stock ticker: MPCCName of primary insider: Dr. Axel SchroederRelation to listed entity: Member of the Board of DirectorsTrade: 29,000 shares purchasedDate: 07.09.2018Average price: NOK 49.40 per sharePrimary insider's total shareholdings post-trade: 149,000 sharesPrimary insider's percentage shareholding post-trade: 0.1768%

Redwood Pharma to present at Nordic Life Science Days in Stockholm on September 11, 2018

On Tuesday, September 11 Redwood Pharma will participate in the Nordic Life Science Days (NLS) Days conference at the Stockholm Waterfront Hotel at 10:24 a.m. CET, Room 24-25.CEO Martin Vidaeus of Redwood Pharma will present the company as well as its RP101 program. The company will also participate in the partnering program to meet potential development and commercial pharmaceutical firms. To register, follow the link: www.nlsdays.com About RP101 and IntelliGel RP101 is the Company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal

Edgeware provides cloud-native containerized TV delivery platform

Software architecture built on cutting edge Docker containers and Kubernetes orchestration delivers full range of ‘mix and match’ deployment options for OTTStockholm, Sweden – September 10, 2018 – Edgeware, the pioneer of online TV delivery systems, announces its first container-based software solutions, which are optimized for public and private cloud platforms. The solutions being delivered as containers are its unique Origin products, TV Content Capture  and TV Repackager . Following

Vicore Pharma expands VP01 (C21) clinical program to enable functional read out

Vicore Pharma (publ) today announced that it will expand its clinical program of lead compound C21, for the treatment of idiopathic pulmonary fibrosis (IPF), to increase the likelihood of showing signals of functional effect and successfully advance C21 in its clinical development.An expansion of the planned clinical phase IIa study in IPF patients – in number of patients, dose and also in treatment duration – is the result of a longer preclinical safety study that has recently been completed. This creates a number of important benefits in relation to the next development phase of C21,

Ovako invests EUR 11 million in Smedjebacken to create new business opportunities

Ovako has decided to invest EUR 11 million in the production plant in Smedjebacken to meet the rising demand for high-quality steel. A new vacuum degassing facility will improve the properties of the steel and create new business opportunities in sectors such as the automotive industry.With support of the new owners Nippon Steel & Sumitomo Metal Corporation, Ovako is continuing to invest in strengthening its position as a world leader in advanced steel solutions. Adding vacuum treatment to the manufacturing process will strengthen the steel and improve its properties, making it suitable for

Read original

Serneke in partnership with construction company in Australia

Serneke becomes a minority owner of Consortium Builders, a local construction company in Perth, Australia."We consider this a pilot project and a first step in our long-term strategy to establish operations in other countries," says Robin Gerum, Head of Business Development at Serneke Group.Serneke currently has its primary focus on expansion in Sweden, but the long-term goal is to establish business in countries outside Sweden. When Serneke now enters into a partnership with Consortium Builders, it is to prepare for this. "We do this as a test to learn how to organize our operations

Summa Equity acquires Lakers

Summa Equity has signed an agreement to acquire Lakers Holding AB (“Lakers”), a Nordic group operating within the water, wastewater, building services and industry segments. The transaction is subject to regulatory approval and is expected to be completed in October 2018.The Nordic water and wastewater infrastructure is ageing and has large inefficiencies. Growing populations, urbanization, increased connectivity and increased regulatory standards also drive the need for restructuring and upgrades of the infrastructure. These challenges will drive growth for Lakers by its contribution to

Powerbox announces precharger solution for railway applications at Innotrans 2018

Powerbox , one of Europe’s largest power supply companies, and for more than four decades a leading force in optimizing power solutions for demanding applications, announces the introduction of its ENR1000-PC series  precharger unit designed to deliver peak power to high capacitive loads in railway applications. The precharger converts the battery nominal bus voltage of 50VDC up to 137.5VDC to a regulated output voltage of 400VDC or 600VDC to charge high voltage capacitor banks used to switch electric valves actuators such

Redeye: Image Systems - Cross-selling in focus

In Q2, Image Systems recovered from a weak Q1 and showed positive EBIDTA. Further, Image Systems acquired the Finnish company Limab Oy (now RemaSawco Oy). The report does not cause us to make any significant changes in our financial forecasts. Read more and download the research update: http://bit.ly/2wYD8ra  Start following companies at Redeye to recieve the latest equity research within Life Science and Technology. This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/

Share buy-backs in Telia Company during week 36 2018

During the period September 3, 2018, until September 7, 2018, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 3 300 000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on April 20, 2018. The share buy-back programme, which runs between April 23, 2018, and March 22, 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (”MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”).During the period

Medivir appoints Dr. Linda Basse as Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Linda Basse as Chief Medical Officer effective October 1, 2018. Dr. Basse will report to CEO Christine Lind and join the Medivir Executive Team. Dr. Basse has more than 18 years of drug development and medical marketing experience, including approvals and marketing of new cancer therapies. Her previous roles include Medical Director at Zealand Pharma with responsibility for an orphan disease drug candidate and Medical Director at Genmab with responsibilities leading to the approval of daratumumab and

There are no items matching the current filter
There are no more items matching the current filter
Back to top